However, our findings do allow assessment of the positive predictive value and 1-year cumulative risk of CRC in increasing ranges of f-Hb for comparison with the 3% threshold outlined by the NICE guidelines for suspected cancer.5 This evidence concerns the gene GSTM1 and cancer.